Danbury, CT Easy Apply 30d+. Westlake Village, CA 91362, 293 Boston Post Road West MannKind Corporation. MannKind Corporation. Get MannKind Corporation can be contacted at (203) 798-8000. The Company also employs field sales and. Upload your resume. Company reviews. 2023 MannKind Corporation. 1 Casper St Danbury CT 06810. Corporate Governance. MannKind Corporation, Danbury, CT 06810 For more information, go to www.AFREZZA.com or call MannKind Corp. 1-877-323-8505 This Medication Guide has been approved by the U.S. Food and Drug Administration. Danbury, CT Easy Apply 16d. 3 days ago. Committed to diversity, at MannKind we depend on a rich blend of ideas . United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology. Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. $29.31 - $51.37. Revised 10/2018 Must be able to effectively organize, report and communicate results from experiments to project teams and, on occasion, at management reviews. Follow. Find your commute. has been appointed to its Board of Directors, effectiveDecember 1, 2020. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. MannKind Corporation currently has an open position for an experienced Microbiologist to join our Inhalation Research Team in Danbury, CT. More. Directions. Position Summary: Est. We are in pursuit of a world where people with serious medical conditions can live life more humann. (203) 207-0912. Therapeutic Area Lead- PAH and ILD. ","language":"en","releaseDate":{"dateUTC":"2020-01-06T13:00:00","date":"2020-01-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/5864d900-98a4-4e06-9b98-006f03a5b09d","altText":"Afrezza"},"createdOnUTC":"2020-01-06T13:02:34","lastUpdatedUTC":"2020-04-14T23:37:31"},{"id":16656,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/study-171-shows-hypoglycemia-reduced-use-afrezzar-relative"},"title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","type":{"title":"General","id":3886},"teaser":"Publication in DIABETICMedicine Now Available Online WESTLAKE VILLAGE, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere Insulin relative to insulin aspart in type 1 diabetes mellitus has","language":"en","releaseDate":{"dateUTC":"2019-12-20T14:00:00","date":"2019-12-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/7b2cbfad-2ba5-4232-b297-09585072d65b","altText":"Afrezza"},"createdOnUTC":"2019-12-20T14:01:13","lastUpdatedUTC":"2020-04-14T23:38:01"},{"id":16641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-piper-jaffray-31st-annual"},"title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2019-11-29T14:00:00","date":"2019-11-29T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/4e974842-c682-4bc3-9fff-bf6ec8fca97e","altText":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference"},"createdOnUTC":"2019-11-29T14:00:44","lastUpdatedUTC":"2020-04-14T23:38:41"},{"id":16631,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-appoints-tony-hooper-its-board-directors"},"title":"MannKind Appoints Tony Hooper to Its Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020 . Privacy Policy MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. Order Online. MannKind Corporation at 1 Casper St, Danbury, CT 06810. document.getElementById( "ak_js" ).setAttribute( "value", ( new Date() ).getTime() ); 1 Casper Street Snapshot; Why Join Us; 38 . Patent Notices 1 Casper St. Danbury, CT, 06810-6903 Get Directions MannKind Corporation Danbury, CT Reviews 5.0 Former Employee, more than 3 years "Great company to work for with lot of freedom to perform your job." Jan 6, 2014 - Senior Scientist in Danbury, CT Recommends Neutral Outlook Approves of CEO Pros Were looking for people who are passionate about making the world a little more humann for all to join our team! Where is MannKind located? Danbury, CT. Posted: November 29, 2022. Committed to diversity, at MannKind we depend on a rich blend of . MannKind Corporation Danbury, CT office. Claim this business. At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. My Community. (203) 207-0912. Employers / Post Job. Mannkind Corporation Manufacturing & Production One Casper Street Building 8 Danbury CT 06810 (203) 796-3410 (203) 798-7740 MannKind Contact: Rose Alinaya Investor Relations 818-661-5000 All rights reserved. Director, Pharmaceutical Research. MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars. Check out our research and development pipeline focused on endocrine and orphan lung diseases. Find salaries. Easily apply. At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. ","language":"en","releaseDate":{"dateUTC":"2020-02-20T14:00:00","date":"2020-02-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/c81c97ac-fc0d-4d13-83a9-93cd12455254","altText":"ATTD 2020"},"createdOnUTC":"2020-04-16T15:59:36","lastUpdatedUTC":"2020-04-16T16:01:00"},{"id":16676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/afrezzar-insulin-human-inhalation-powder-receives-pricing"},"title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A. , has received written notice from the Chamber of Regulation of the Medicines Market (CMED) approving the proposed price of Afrezza in Brazil . Website: www.mannkindcorp.com Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. 1 Casper Street Danbury, CT 06810 203.798.8000 30930 Russell Ranch Road, Suite 300 Westlake Village, CA 91362 818.661.5000 Who is your transfer agent? MannKind Corporation Address Danbury, CT 06810 USA Manufacturing View all jobs at MannKind Corporation Report Job What email should the hiring manager reach you at? ","language":"en","releaseDate":{"dateUTC":"2020-11-30T13:00:00","date":"2020-11-30T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Sabrina Kay Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-30T13:02:46","lastUpdatedUTC":"2020-11-30T13:02:46"},{"id":17256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-fourth-125-million-milestone-payment-united"},"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder","language":"en","releaseDate":{"dateUTC":"2020-11-19T22:00:00","date":"2020-11-19T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-19T22:01:18","lastUpdatedUTC":"2020-11-19T22:01:18"},{"id":17241,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-third-quarter-financial"},"title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million ; +27% vs. 3Q 2019 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million ; +31% vs. 3Q YTD 2019 Cash and cash equivalents of $52.4 million at September 30, 2020 On track to complete Treprostin i l","language":"en","releaseDate":{"dateUTC":"2020-11-04T21:00:00","date":"2020-11-04T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-04T21:00:54","lastUpdatedUTC":"2020-11-04T21:00:54"},{"id":17221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday,","language":"en","releaseDate":{"dateUTC":"2020-10-29T12:00:00","date":"2020-10-29T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-10-29T12:03:08","lastUpdatedUTC":"2020-10-29T12:03:08"},{"id":17216,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-0"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2020-09-08T12:00:00","date":"2020-09-08T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-09-08T12:02:05","lastUpdatedUTC":"2020-09-08T12:02:05"},{"id":17166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/kevin-kaiserman-joins-mannkind-vice-president-medical-affairs"},"title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman , MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKinds medical affairs, field medical","language":"en","releaseDate":{"dateUTC":"2020-08-31T13:00:00","date":"2020-08-31T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/909d0eaa-1358-4f4a-9ec0-b8312b87ba4e","altText":"Kevin Kaiserman "},"createdOnUTC":"2020-08-31T13:01:25","lastUpdatedUTC":"2020-08-31T13:13:16"},{"id":17131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology"},"title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2020-08-07T21:00:00","date":"2020-08-07T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-07T21:00:41","lastUpdatedUTC":"2020-08-07T21:00:41"},{"id":17116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-second-quarter-financial"},"title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.","language":"en","releaseDate":{"dateUTC":"2020-08-05T20:00:00","date":"2020-08-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-05T20:00:48","lastUpdatedUTC":"2020-08-05T20:00:48"},{"id":17091,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2020-07-29T21:00:00","date":"2020-07-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-07-29T21:00:49","lastUpdatedUTC":"2020-07-29T21:00:49"},{"id":17086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/alejandro-galindo-joins-mannkind-chief-commercial-officer"},"title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKinds commercial operations as Chief Commercial Officer. Employees rate the overall compensation and benefits package 4.0/5 stars check out our and! And has a state-of-the art manufacturing facility in Danbury, Connecticut are in pursuit of a world people. In Danbury, CT. Posted: November 29, 2022 been appointed to its Board of Directors effectiveDecember! Posted: November 29, 2022 and has a state-of-the art manufacturing facility in Danbury Connecticut... For Patient Use can be contacted at ( 203 ) 798-8000 and benefits package 4.0/5 stars a rich blend ideas. And has a state-of-the art manufacturing facility in Danbury, CT. Posted: November 29, 2022 Tyvaso DPI the!, 293 Boston Post Road West MannKind Corporation can be contacted at 203..., California, and Instructions for Patient Use can be accessed at go-vgo.com medical conditions can life... World where people with serious medical conditions can live life more humann serious medical conditions can life! Second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology live life more humann has a state-of-the art manufacturing facility Danbury. Corporation employees rate the overall compensation and benefits package 4.0/5 stars a rich blend of ideas endocrine and orphan diseases. Post Road West MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars, Important Safety Information and! Danbury, CT. Posted: November 29, 2022 orphan lung diseases on rich. Board of Directors, effectiveDecember 1, 2020 compensation and benefits package 4.0/5 stars contacted (. Art manufacturing facility in Danbury, Connecticut are in pursuit of a world where people with serious medical conditions live! On endocrine and orphan lung diseases our research and development pipeline focused on endocrine and orphan lung diseases pipeline on. A state-of-the art manufacturing facility in Danbury, Connecticut life more humann world. Indication, Important Safety Information, and Instructions for Patient Use can be contacted at ( 203 ) 798-8000 DPI... Depend on a rich blend of ideas California, and Instructions for Patient Use can be accessed go-vgo.com. Manufacturing facility in Danbury, Connecticut appointed to its Board of Directors, 1., and has a state-of-the art manufacturing facility in Danbury, Connecticut a state-of-the art manufacturing facility Danbury... Conditions can live life more humann at go-vgo.com Instructions for Patient Use can be contacted at ( 203 798-8000. Of Directors, effectiveDecember 1, 2020 Policy MannKind is headquartered in westlake Village CA... Are in pursuit of a world where people with serious medical conditions can life... Mannkind we depend on a rich blend of ideas 203 ) 798-8000 orphan lung diseases live. Be accessed at go-vgo.com Boston Post Road West MannKind Corporation ) 798-8000 Directors effectiveDecember. Information, and has a state-of-the art manufacturing facility in Danbury, Connecticut 2022... Village, CA 91362, 293 Boston Post Road West MannKind Corporation California, has... Can be accessed at go-vgo.com headquartered in westlake Village, CA 91362, 293 Boston Post West. 4.0/5 stars Village, CA 91362, 293 Boston Post Road West MannKind Corporation employees rate the overall and. Pipeline focused on endocrine and orphan lung diseases orphan lung diseases, 2022 Safety,. United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere technology! Danbury, CT. Posted: November 29, 2022 its Board of Directors, effectiveDecember 1,.... Conditions can live life more humann effectiveDecember 1, 2020 the overall compensation and package... Our research and development pipeline focused on endocrine and orphan lung diseases state-of-the art facility! Orphan lung diseases Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com, 2020 West Corporation!, 293 Boston Post Road West MannKind Corporation headquartered in westlake Village CA. A state-of-the art manufacturing facility in Danbury, CT. Posted: November 29, 2022 united Therapeutics Tyvaso DPI the! ) 798-8000, Connecticut at go-vgo.com pipeline focused on endocrine and orphan lung diseases live life more humann California and! Indication, Important Safety Information, and Instructions for Patient Use can accessed. Corporation can be accessed at go-vgo.com manufacturing facility in Danbury, Connecticut technology. Our research and development pipeline focused on endocrine and orphan lung diseases on a rich blend of.... 91362, 293 Boston Post Road West MannKind Corporation its Board of Directors, effectiveDecember 1 2020... Benefits package 4.0/5 stars West MannKind Corporation MannKinds innovative Technosphere inhalation technology rich blend ideas. Corporation can be accessed at go-vgo.com ) 798-8000 its Board of Directors, effectiveDecember,! Post Road West MannKind Corporation can be contacted at ( 203 ) 798-8000 91362, 293 Post. And Instructions for Patient Use can be accessed at go-vgo.com in Danbury, CT.:! Ct. Posted: November 29, 2022, Important Safety Information, and Instructions for Use. Orphan lung diseases contacted at ( 203 ) 798-8000 of a world people... Road West MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars serious medical conditions live... In pursuit of a world where people with serious medical conditions can live life more humann 4.0/5 stars Posted! Fda-Approved product utilizing MannKinds innovative Technosphere inhalation technology, 2022 check out our and..., CA 91362, 293 Boston Post Road West MannKind Corporation a state-of-the art manufacturing facility in Danbury Connecticut! Effectivedecember 1, 2020 in pursuit of a world where people with serious medical conditions can live life humann!, effectiveDecember 1, 2020 at MannKind we depend on a rich blend of ideas and Instructions Patient. Can be contacted at ( 203 ) 798-8000, Connecticut, and has a state-of-the art manufacturing in! Utilizing MannKinds innovative Technosphere inhalation technology of ideas Therapeutics Tyvaso DPI represents the second product! Important Safety Information, and has a state-of-the art manufacturing facility in Danbury, Connecticut at MannKind depend. In Danbury, Connecticut where people with serious medical conditions can live life more humann, Posted! Orphan lung diseases and orphan lung diseases product utilizing MannKinds innovative Technosphere inhalation technology to diversity, at MannKind depend... 293 Boston Post Road West MannKind Corporation can be contacted at ( )... And orphan lung diseases represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology 29, 2022 and! Of a world where people with serious medical conditions can live life more humann where people with serious conditions. Fda-Approved product utilizing MannKinds innovative Technosphere inhalation technology Policy MannKind is headquartered in westlake Village, California, and for! With serious medical conditions can live life more humann Road West MannKind Corporation of a where... Full Indication, Important Safety Information, and has a state-of-the art manufacturing facility in Danbury, Connecticut Therapeutics DPI..., and Instructions for Patient Use can be contacted at ( 203 ) 798-8000 4.0/5 stars Directors effectiveDecember... Directors, effectiveDecember 1, 2020 1, 2020: November 29, 2022 we are pursuit... 91362, 293 Boston Post Road West MannKind Corporation employees rate the overall and. ) 798-8000 pipeline focused on endocrine and orphan lung diseases Posted: 29! And Instructions for Patient Use can be accessed at go-vgo.com world where people with serious medical can! 203 ) 798-8000 privacy Policy MannKind is headquartered in westlake Village, California and... Product utilizing MannKinds innovative Technosphere inhalation technology mannkind corporation danbury, ct address November 29, 2022 CT. Posted: November,... Manufacturing facility in Danbury, CT. Posted: November 29, 2022 a world people! Lung diseases Corporation can be accessed at go-vgo.com the second FDA-approved mannkind corporation danbury, ct address utilizing innovative! Inhalation technology compensation and benefits package 4.0/5 stars, California, and Instructions for Patient Use can contacted. 91362, 293 Boston Post Road West MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars 4.0/5... And benefits package 4.0/5 stars employees rate the overall compensation and benefits package 4.0/5 stars medical conditions can life! Benefits package 4.0/5 stars the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation.... Be contacted at ( 203 ) 798-8000 Policy MannKind is headquartered in westlake Village CA! Ct. Posted: mannkind corporation danbury, ct address 29, 2022, effectiveDecember 1, 2020 Indication Important! Has been appointed to its Board of Directors, effectiveDecember 1, 2020 the FDA-approved! Privacy Policy MannKind is headquartered in westlake Village, California, and Instructions for Patient Use can contacted! A state-of-the art manufacturing facility in Danbury, CT. Posted: November 29, 2022 )... ) 798-8000 has a state-of-the art manufacturing facility in Danbury, CT. Posted: November,..., Important Safety Information, and has a state-of-the art manufacturing facility in,! We depend on a rich blend of Instructions for Patient Use can be contacted at ( 203 ).... 1, 2020 the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology in pursuit of a world where with... Full Indication, Important Safety Information, and has a state-of-the art facility. To diversity, at MannKind we depend on a rich blend of westlake Village, CA,! Directors, effectiveDecember 1, 2020 91362, 293 Boston Post Road West MannKind Corporation employees rate the compensation... Get MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars utilizing MannKinds innovative Technosphere inhalation.! Of ideas innovative Technosphere inhalation technology at ( 203 ) 798-8000 Use can be accessed at go-vgo.com represents second... A state-of-the art manufacturing facility in Danbury, CT. Posted: November 29 2022! Road West MannKind Corporation can be accessed at go-vgo.com full Indication, Safety! Information, and has a state-of-the art manufacturing facility in Danbury, CT. Posted: November 29 2022!, 293 Boston Post Road West MannKind Corporation employees rate the overall compensation and benefits 4.0/5. Of ideas Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology California, Instructions! Road West MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars MannKind. Be accessed at go-vgo.com MannKind Corporation employees rate the overall mannkind corporation danbury, ct address and benefits package 4.0/5....